Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant: Comparison to levonorgestrel-releasing subdermal implant

Human Reproduction

Volumn 31, Issue 11, 2016, Pages 2491-2498

  Ali, Moazzam ^a   Akin, Ayse ^b   Bahamondes, Luis ^c   Brache, Vivian ^d   Habib, Ndema ^a   Landoulsi, Sihem ^a   Hubacher, David ^e  

^a UNICEF   (United States)

^b BASKENT UNIVERSITY   (Turkey)

^c UNIVERSITY OF CAMPINAS   (Brazil)

^d PROFAMILIA   (Dominican Republic)

^e NONE   (United States)

Author keywords

etonogestrel; extended use; intrauterine device; levonorgestrel; subdermal contraceptive implants

Indexed keywords

ETONOGESTREL; LEVONORGESTREL; CONTRACEPTIVE AGENT; DESOGESTREL;

ACNE; ADULT; AMENORRHEA; ARTICLE; CONTROLLED STUDY; COPPER INTRAUTERINE DEVICE; DEVICE REMOVAL; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; ETONOGESTREL RELEASING SUBDERMAL CONTRACEPTIVE IMPLANT; FEMALE; FEMALE CONTRACEPTIVE DEVICE; HEADACHE; HUMAN; LEVONORGESTREL RELEASING SUBDERMAL IMPLANT; LOWER ABDOMINAL PAIN; MENORRHAGIA; MENSTRUAL IRREGULARITY; MULTICENTER STUDY; PREGNANCY RATE; RANDOMIZED CONTROLLED TRIAL; ADOLESCENT; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG IMPLANT; FAMILY PLANNING; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; CONTRACEPTIVE AGENTS, FEMALE; DESOGESTREL; DRUG IMPLANTS; FAMILY PLANNING SERVICES; FEMALE; HUMANS; LEVONORGESTREL; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84996484068     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/dew222     Document Type: Article

References (10)

1. Bahamondes L, Brache V, Meirik O, Ali M, Habib N, Landoulsi S; WHO Study Group on Contraceptive Implants for Women. A 3-year multicentre randomized controlled trial of etonogestrel-and levonorgestrelreleasing contraceptive implants, with non-randomized matched copper-intrauterine device controls. Hum Reprod 2015;30:2527-2538.
2. Diaz S, Pavez M, Moo-Young AJ, Bardin CW, Croxatto HB. Clinical trial with 3-keto-desogestrel subdermal implants. Contraception 1991;44: 393-408.
3. Huber J, Wenzl R. Pharmacokinetics of Implanon. An integrated analysis. Contraception 1998;58:85S-90S. Implanon Prescribing Information. http://www. implanon-usa. com/en/ consumer/main/prescribing-information. xhtmlhttps://www. merck. com /product/usa/pi-circulars/i/implanon/implanon-pi. pdf (6 May 2016, date last accessed).
4. Kiriwat O, Patanayindee A, Koetsawang S, Korver T, Bennink HJ. A 4-year pilot study on the efficacy and safety of Implanon, a single-rod hormonal contraceptive implant, in healthy women in Thailand. Eur J Contracept Reprod Health Care 1998;3:85-91.
5. McNicholas C, Maddipati R, Zhao Q, Swor E, Peipert JF. Use of the etonogestrel implant and levonorgestrel intrauterine device beyond the U. S. Food and Drug Administration-approved duration. Obstet Gynecol 2015; 125:599-604.
6. Reproductive Health Supplies Coalition RHInterchange Website. http://rhi. rhsupplies. org/rhi/index. do?locale=en-US (6 May 2016, date last accessed).
7. Wenzl R, van Beek A, Schnabel P, Huber J. Pharmacokinetics of etonogestrel released from the contraceptive implant Implanon. Contraception 1998;58:283-288.
8. Weisberg E, Bateson D, McGeechan K, Mohapatra L. A three-year comparative study of continuation rates, bleeding patterns and satisfaction in Australian women using a subdermal contraceptive implant or progestogen releasing-intrauterine system. Eur J Contracept Reprod Health Care 2014;19:5-14.
9. World Health Organization. Medical eligibility criteria for contraceptive use. In: Reproductive Health and Research, 2nd edn. Geneva: World Health Organization, 2000.
10. Zheng SR, Zheng HM, Qian SZ, Sang GW, Kaper RF. A long-term study of the efficacy and acceptability of a single-rod hormonal contraceptive implant (Implanon) in healthy women in China. Eur J Contracept Reprod Health Care 1999;4:85-93.